Call Us
1 833- 4 3 6 2 2 6 6 
News & Media
Geocann and Averix Bio form a strategic partnership to supply the global marketplace with pharmaceutical API phytocannabinoid ingredients formulated with a clinically proven drug delivery system technology

Geocann and Averix Bio form a strategic partnership to supply the global marketplace with pharmaceutical API phytocannabinoid ingredients formulated with a clinically proven drug delivery system technology

Posted on
April 13, 2022

The partnership will allow Geocann to have the exclusive distribution rights of Averix Bio phytocannabinoid ingredients inthe rapidly evolving South American marketplace where they will offer pharmaceuticalAPI starting materials, available as either stand-alone ingredients or clinically proven VESIso formulations.

Geocann is proud to announce a strategic partnership with Averix Bio that will bring U.S.-produced API phytocannabinoid ingredients and clinically proven bioavailable formulations to the global marketplace. This partnership allows both companies to become first movers to bridge an inevitable gap with the largest organizations in the pharmaceutical, nutraceutical, cosmetic, and veterinary sectors. The alliance has a laser focus on South America as Geocann has established a sales, distribution, and marketing infrastructure to support leading human and animal nutrition brands.

“Forming partnerships with ingredient manufacturers who deeply value compliance and quality is one of Geocann’s top responsibilities to our global network of brand partners and contract manufacturers that has been built over the past 40 years,” Jesse Lopez, CEO and founder of Geocann said. “Our new partnership with Averix Bio is an important milestone in the cannabis industry and allows us to serve our network with pharmaceutical API phytocannabinoid ingredients that can be formulated with the VESIsorb® technology in a wide range of product applications, including capsules, sublinguals, cosmetics, functional foods, and wellness beverages.” 

The strategic partnership comes on the heels of Averix Bio’s recent achievements that demonstrate the highest levels of regulatory compliance, including:

  • 21 CFR Part 210 and Part 211;
  • ICH Q7;
  • 200-level cGMP; and
  • FDA Drug Master File (DMF 036798).
“Geocann and its associated non-cannabis companies have an unrivaled reputation for taking the best starting materials and optimizing their therapeutic benefits by leveraging a strong intellectual property portfolio,” Miles Wright, CEO of Averix Bio said. “There is not a close second to Geocann in regards to organizations serving the cannabis industry with technical formulation know-how, a strong body of supporting scientific evidence, and a trusted distribution network. Armed with strong clinical research and an unmatched global partner technology exchange that is bolstered by the multi-patented VESIsorb drug delivery system, Geocann is the perfect partner to exclusively represent Averix Bio cannabinoid ingredients in South America.” 

Geocann also has the exclusive global rights to the VESIsorb® drug delivery system technology for cannabinoids, terpenes, and flavonoid formulations. The technology has been well-recognized as the industry leader for improving the bioavailability of poorly absorbed ingredients. Most recently, the peer-reviewed journal, Molecules, published the results of a double-blind, cross-over design study (Knaub et al., Molecules 24,2967, 2019) demonstrating statistically significant improvements for all measured pharmacokinetic (PK) parameters of cannabinoids formulated withVESIsorb technology compared to that of the same cannabinoids combined with medium chain triglyceride (MCT) oil.

  • VESIsorb® formulation is superior regarding Tmax ("fast acting within one hour").
  • VESIsorb® formulation is demonstrated the highest Cmax.
  • VESisorb® formulation demonstrated the highest AUC.
  • VESisorb® formulation addressed factors relating to poor CBD pharmacokinetics including gender and diet.

In addition to this PK study, Lopez confirmed that Geocann and Averix Bio have agreed on new research initiatives related to product safety andperformance that are already underway.